Coagulation factor XIIIa substrates in human plasma: identification and incorporation into the clot
- PMID: 24443567
- PMCID: PMC3945317
- DOI: 10.1074/jbc.M113.517904
Coagulation factor XIIIa substrates in human plasma: identification and incorporation into the clot
Abstract
Coagulation factor XIII (FXIII) is a transglutaminase with a well defined role in the final stages of blood coagulation. Active FXIII (FXIIIa) catalyzes the formation of ε-(γ-glutamyl)lysine isopeptide bonds between specific Gln and Lys residues. The primary physiological outcome of this catalytic activity is stabilization of the fibrin clot during coagulation. The stabilization is achieved through the introduction of cross-links between fibrin monomers and through cross-linking of proteins with anti-fibrinolytic activity to fibrin. FXIIIa additionally cross-links several proteins with other functionalities to the clot. Cross-linking of proteins to the clot is generally believed to modify clot characteristics such as proteolytic susceptibility and hereby affect the outcome of tissue damage. In the present study, we use a proteomic approach in combination with transglutaminase-specific labeling to identify FXIIIa plasma protein substrates and their reactive residues. The results revealed a total of 147 FXIIIa substrates, of which 132 have not previously been described. We confirm that 48 of the FXIIIa substrates were indeed incorporated into the insoluble fibrin clot during the coagulation of plasma. The identified substrates are involved in, among other activities, complement activation, coagulation, inflammatory and immune responses, and extracellular matrix organization.
Keywords: Blood Coagulation Factors; Fibrinogenesis; Plasma; Proteomics; Transglutaminases.
Figures


Similar articles
-
Substrates of Factor XIII-A: roles in thrombosis and wound healing.Clin Sci (Lond). 2013 Feb;124(3):123-37. doi: 10.1042/CS20120233. Clin Sci (Lond). 2013. PMID: 23075332 Review.
-
Proteolytic and nonproteolytic activation mechanisms result in conformationally and functionally different forms of coagulation factor XIII A.FEBS J. 2020 Feb;287(3):452-464. doi: 10.1111/febs.15040. Epub 2019 Aug 28. FEBS J. 2020. PMID: 31407850 Free PMC article.
-
Human complement C3 is a substrate for transglutaminases. A functional link between non-protease-based members of the coagulation and complement cascades.Biochemistry. 2012 Jun 12;51(23):4735-42. doi: 10.1021/bi3004022. Epub 2012 Jun 4. Biochemistry. 2012. PMID: 22630814
-
[Methods for the determination of factor XIII/XIIIa].Hamostaseologie. 2002 Feb;22(1):32-42. Hamostaseologie. 2002. PMID: 12193983 Review. German.
-
GKVLAK–(Gadolinium-(1,4,7,10-tetraazacyclododecane-1,4,7-tris(acetic acid t-butyl ester)-10-acetic acid monoamide))–GGGGTVQQEL.2011 Mar 29 [updated 2011 Apr 26]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2011 Mar 29 [updated 2011 Apr 26]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 21542560 Free Books & Documents. Review.
Cited by
-
Inhibition of Fibrinolysis by Coagulation Factor XIII.Biomed Res Int. 2017;2017:1209676. doi: 10.1155/2017/1209676. Epub 2017 Jul 6. Biomed Res Int. 2017. PMID: 28761875 Free PMC article. Review.
-
Coagulation, inflammation, and CD46 transgene expression in neonatal porcine islet xenotransplantation.Xenotransplantation. 2021 May;28(3):e12680. doi: 10.1111/xen.12680. Epub 2021 Feb 22. Xenotransplantation. 2021. PMID: 33619844 Free PMC article.
-
Advances of Coagulation Factor XIII.Chin Med J (Engl). 2017 Jan 20;130(2):219-223. doi: 10.4103/0366-6999.198007. Chin Med J (Engl). 2017. PMID: 28091415 Free PMC article. Review.
-
Functionalizing Fibrin Hydrogels with Thermally Responsive Oligonucleotide Tethers for On-Demand Delivery.Bioengineering (Basel). 2022 Jan 10;9(1):25. doi: 10.3390/bioengineering9010025. Bioengineering (Basel). 2022. PMID: 35049734 Free PMC article.
-
Factor XIIIa inhibitors as potential novel drugs for venous thromboembolism.Eur J Med Chem. 2020 Aug 15;200:112442. doi: 10.1016/j.ejmech.2020.112442. Epub 2020 May 18. Eur J Med Chem. 2020. PMID: 32502864 Free PMC article. Review.
References
-
- Lippi G., Franchini M., Targher G. (2011) Arterial thrombus formation in cardiovascular disease. Nat. Rev. Cardiol. 8, 502–512 - PubMed
-
- Lorand L. (2001) Factor XIII. Structure, activation, and interactions with fibrinogen and fibrin. Ann. N.Y. Acad. Sci. 936, 291–311 - PubMed
-
- Muszbek L., Bereczky Z., Bagoly Z., Komáromi I., Katona E. (2011) Factor XIII. A coagulation factor with multiple plasmatic and cellular functions. Physiol. Rev. 91, 931–972 - PubMed
-
- Lorand L., Graham R. M. (2003) Transglutaminases. Crosslinking enzymes with pleiotropic functions. Nat. Rev. Mol. Cell Biol. 4, 140–156 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources